Evaluation of a Microfluidic System for Performance of Fully Automated Companion Diagnostics for Personalized Medicine

Transcription

1 Evaluation of a Microfluidic System for Performance of Fully Automated Companion Diagnostics for Personalized Medicine Gwendolyn Spizz, I. Cristina McGuire, Rubina Yasmin, Whitney Honey, Zongyuan Chen, Richard Montagna and Peng Zhou Rheonix, Inc. 22 Thornwood Drive, Ithaca, New York Presented by: Richard A. Montagna, Ph.D. Senior VP, Corporate Business Development Rmontagna@rheonix.com

2 Rheonix CARD Technology Fully automated molecular diagnostics No hands on efforts required Inclusive of all preparative, analytical and readout steps. Reduces time and cost of molecular diagnostic testing Multiple applications, including personalized medicine/companion diagnostics CARD Chemistry and Reagent Device

3 Building the CARD Fully integrated plastic disposable contains all required functional capabilities Achieved by patented lamination process

4 Pumps or Valves Based on software commands, individual diaphragms can operate as open valves, closed valves or bi directional pumps. Pump 3 diaphragms actuated sequentially

5 Creation of Microfluidic Networks 4 Diaphragms form 3 Bidirectional Pumps >1> >1>4 3 2>1>4 4 3 Multiple diaphragm configurations can be customized to create simple or complex fluidic web networks

6 CARD Components C Reservoir cartridge Fluidic layer Film layer Reactor attachment layer Reactor attachment rings Lumens Amplification reactors

7 EncompassMDx Workstation

8 Sample Types/Volumes Sample Types Whole Blood Serum Plasma Saliva Buccal Swabs Vaginal Swab Whole Tissue Fresh & FFPE Volumes 5 µl 5 ml

9 Personalized Medicine Applications Not 510(k) cleared for in vitro diagnostics (yet!!) Using genomic data to predict sensitivity to and/or responsiveness to various drugs. Warfarin sensitivity Cyp2C9*2, Cyp2C9*3, VKORC1 Whole blood or buccal swabs Plavix sensitivity Cyp2C19*2, Cyp2C19*3 Whole blood or buccal swabs EGFR inhibitors (Erbitux/Vectibix) Single nucleotide changes within Exon 2 at positions 34, 35, 37, 38 (G>A>C>T) codons 12 and 13. FFPE Tissue block

10 Automated CARD Processes Introduce raw sample. Automatically process ( sample-to-results ) Untreated raw Sample Lyse cells Extract/purify DNA Multiplex PCR with biotinylated primers Denature amplicons Detect amplicons on DNA Array using RDB

11 Rheonix Warfarin PGx Assay Raw sample is 5 µl whole blood 3 SNPs evaluated CYP2C9*2 CYP2C9*3 VKOR1 3 possible genotypes at each loci WT/WT WT/Mut Mut/Mut Genomic calls made by software Results have been confirmed against bidirectional sequencing. Will enter US clinical studies soon.

12 Rheonix Warfarin PGx Assay Microarray Key Spotting control Spotting control Spotting control CYP2C9*2 WT CYP2C9*2 WT VKORC1 WT CYP2C9*2 Mut CYP2C9*2 Mut VKORC1 Mut CYP2C9*3 WT CYP2C9*3 WT VKORC1 WT CYP2C9*3 Mut CYP2C9*3 Mut VKORC1 Mut Spotting control WT WT Het WT Mut Het CYP2C9*2 WT Het WT Mut WT Het CYP2C9*3 WT WT Mut Het Het Het VKORC1

13 Distinguishing Genotypes Mutant Relative Intensity Het Mut WT Homozygous Genotype: Homozygous Wildtype Heterozygous Mutant WT WT Mut Mut Wild Type Relative Intensity

14 Upcoming Clinical Studies Four clinical study sites Mayo Clinic (Rochester, MN) Strong Memorial Hospital (Rochester, NY) Catholic Hospital System (Buffalo, NY) Rheonix, Inc. (Ithaca, NY) Bi-directional DNA Sequencing lab Center of Excellence (Buffalo, NY) Intend to submit clinical data in a 510(k) application to support claims for Rheonix Warfarin PGx Assay and EncompassMDX instrument.

15 Plavix PGx Assay CYP2C19*2/CYP2C19*3 CYP2C19 RDB Filter Key SC-T SC-T SC-T 2C19*2WT 2C19*2WT 2C19*2WT 2C19*2WT 2C19*2WT 2C19*2WT 2C19*2MUT 2C19*2WT 2C19*2WT 2C19*2MUT 2C19*2MUT 2C19*2WT 2C19*2WT 2C19*2MUT 2C19*3WT 2C19*2WT 2C19*2WT 2C19*3MUT 2C19*3WT 2C19*3WT 2C19*3MUT_S_T 2C19*3MUT 2C19*3WT 2C19*3MUT_S_T SC-T WT MUT HET WT HET MUT WT WT WT WT WT WT WT WT WY WT HET HET HET HET CYP2C19 *2 CYP2C19 *3

16 FFPE Sample-to-Results Raw sample DNA Isolation PCR 10 µm microtome Sample processing FFPE Block Place in CARD Lysis and PCR RDB microassay Detection on DNA microarray

17 FFPE/KRAS Detection Raw Sample KRAS Filter Key Spotting Control Spotting Control Spotting Control 34 WT 35 WT 37 WT 34 G>A 34 G>C 34 G>T 34 G>A 34 G>C 34 G>T 35 G>A 35 G>C 35 G>T 35 G>A 35 G>C 35 G>T 38 G>A BRAFMUT1 38 WT 38 G>A BRAFMUT1 BRAF WT Spotting Control Results 34 G>A 34 G>A

18 FFPE/KRAS Detection Raw Sample KRAS Filter Key Spotting Control Spotting Control Spotting Control 34 WT 35 WT 37 WT 34 G>A 34 G>C 34 G>T 34 G>A 34 G>C 34 G>T 35 G>A 35 G>C 35 G>T 35 G>A 35 G>C 35 G>T 38 G>A BRAFMUT1 38 WT 38 G>A BRAFMUT1 BRAF WT Spotting Control Results 35 G>A 35 G>A

19 Technical/Financial Benefits Rheonix CARD Technology is fully automated Reduces training requirements and costs Inexpensive Capital Equipment and Disposable costs No need for additional equipment CARDs are produced by injection molding Overall technology will dramatically lower the cost per reportable result

20 Thank you Contact Information: Richard A. Montagna, Ph.D. Senior VP, Corporate Business Development , Ext. 11